Compare Salesforce Inc (CRM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Novo Nordisk A/S — how do they compare? Salesforce Inc trades at $229.13 (market cap $187.48B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Salesforce Inc and Novo Nordisk A/S are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Novo Nordisk A/S for 116 Days on average.
| CRM | NVO | |
|---|---|---|
Market Cap | $187.48B | $165.31B |
Volume | 6,155,822 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $266.23 | $63.98 |
52-Week Low | $150.12 | $35.29 |
Typical Hold Time | 89 Days | 116 Days |
Enterprise Value | $217.82B | $179.56B |
Dividend Yield | 0.77% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $227.80, up 1.44% with strong fundamentals including 77.28% gross margins and consistent earnings beats. The stock shows bearish technical signals but maintains robust revenue growth trajectory from $37.9B in 2025 to projected $43.9B in 2026. Recent AI-driven innovations like Agentforce and Data 360 show promising monetization potential with $2.9B ARR growth.
Despite technical headwinds, Salesforce presents compelling value with 76.5% analyst buy ratings and $271.91 price target representing 19% upside. Key risks include AI competition pressure and software sector volatility, but strong cash flow generation and market leadership support long-term growth prospects.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
